Par Pharmaceutical announced that it has acquired rights to market and distribute Handa’s dexlansoprazole capsules, the generic version of Takeda‘s Dexilant.

Under the terms of the agreement, Par made a payment to Handa for the ANDA, giving it the exclusive rights to market, sell and distribute dexlansoprazole capsules in the US under the ANDA, subject to final FDA approval.  Par will receive a percentage of profits from the sales of the product. 

Dexilant is indicated in healing of all grades of erosive esophagitis (EE), treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), maintenance of healing of EE and relief of heartburn.

For more information call (800) 828-9393 or visit